KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Long-Term Debt Repayments (2017 - 2025)

Historic Long-Term Debt Repayments for Teva Pharmaceutical Industries (TEVA) over the last 11 years, with Q3 2025 value amounting to $444.0 million.

  • Teva Pharmaceutical Industries' Long-Term Debt Repayments changed N/A to $444.0 million in Q3 2025 from the same period last year, while for Dec 2025 it was $4.1 billion, marking a year-over-year increase of 15057.89%. This contributed to the annual value of $4.1 billion for FY2025, which is 15057.89% up from last year.
  • According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' Long-Term Debt Repayments is $444.0 million.
  • Teva Pharmaceutical Industries' 5-year Long-Term Debt Repayments high stood at $5.2 billion for Q4 2021, and its period low was $296.0 million during Q2 2022.
  • In the last 5 years, Teva Pharmaceutical Industries' Long-Term Debt Repayments had a median value of $978.0 million in 2023 and averaged $1.5 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Long-Term Debt Repayments crashed by 8631.62% in 2022 and then surged by 17397.26% in 2023.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Long-Term Debt Repayments stood at $5.2 billion in 2021, then plummeted by 86.32% to $708.0 million in 2022, then soared by 41.24% to $1.0 billion in 2023, then tumbled by 31.5% to $685.0 million in 2024, then plummeted by 35.18% to $444.0 million in 2025.
  • Its Long-Term Debt Repayments stands at $444.0 million for Q3 2025, versus $2.3 billion for Q2 2025 and $1.4 billion for Q1 2025.